On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk...
On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk...
2024 年 5 月 5 日，强生公司更新了多队列 1 期安全性和有效性研究的结果；TAR-210 结果显示，在高风险和中等风险患者中，有 90% 的无复发存活率和 90% 的完全缓解...
On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Respectively
2024 年 5 月 5 日，强生更新了多队列 1 期安全性和有效性研究的结果；TAR-210 结果显示，高风险和中等风险非肌肉浸润性膀胱癌患者分别有 90% 的无复发存活率和 90% 的完全缓解
Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations
最新结果增强了 TAR-210 改变非治疗方法的潜力—伴有成纤维细胞生长因子受体的肌肉浸润性膀胱癌 (FGFR) 改变
SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local...
圣安东尼奥，2024 年 5 月 5 日 /PRNewswire/ — 强...
登录免费看全文
登录/注册